IBM Jumps 7%; IonQ, Rigetti Sell Off as Quantum Trade Concentrates

IBM surged to about $320, gaining 32% in May after announcing a $10 billion five-year quantum computing commitment and a $1 billion CHIPS Act grant-backed foundry plan aimed at a fault-tolerant quantum computer by 2029. IBM also reported Q1 revenue of $15.9 billion, while IonQ and Rigetti fell about 4% despite strong revenue growth and raised guidance, reflecting a rotation of capital into IBM's scale and government-backed quantum strategy.

Analysis

The key move is not “quantum is hot,” but that capital is now discriminating between monetizable platform scale and pure-play option value. IBM is becoming the institutional wrapper for the theme: it offers policy optionality, enterprise distribution, and a balance-sheet-backed path to absorb long-duration capex, while the pure-plays remain funding-dependent and more exposed to a sentiment unwind once the next growth print is not enough to justify valuation expansion.

Second-order, the CHIPS-linked foundry angle changes the competitive map. If IBM can credibly control more of the stack, it reduces reliance on third-party manufacturing and increases switching costs for adjacent ecosystem players like SKYT and the broader semiconductor supply chain; the read-through to GFS is positive only to the extent U.S. government support keeps flowing into domestic foundry capacity. The market is effectively pricing a higher probability that quantum becomes an industrial policy winner before it becomes a stand-alone earnings story.

The pullback in IONQ and RGTI looks more like a positioning shakeout than a fundamental break, but that cuts both ways. These names have already priced in a lot of future success, so any delay in commercialization, acquisition integration, or capex conversion can produce 15-25% drawdowns quickly, especially after multi-week momentum runs. By contrast, IBM’s upside is more measured but also less fragile: it can rerate on execution progress without needing perfect quarter-over-quarter hypergrowth.

Consensus may be underestimating how much of the current move is a flow event anchored to government affiliation rather than true near-term quantum economics. If the broader market rotates out of speculative growth over the next 1-3 months, IBM should retain relative support while IONQ and RGTI remain vulnerable to multiple compression. The contrarian risk on IBM is that the stock has already pulled forward several years of narrative value, so a missed timeline update on fault-tolerant milestones could quickly turn today’s institutional bid into a valuation air pocket.

Key Decisions for Investors

• Long IBM vs. short IONQ in a 6-12 week pair trade: favor IBM’s lower funding risk and policy-backed optionality over IONQ’s higher beta; use a 2:1 notional ratio and cover if IBM loses the $320 area on sustained volume.
• Add tactical long IBM calls or call spreads for the next 1-2 months: the setup is momentum/flow-driven, but cap risk by using defined premium since upside likely comes from rerating rather than explosive earnings revisions.
• Fade extended pure-play quantum strength on rallies: short-dated put spreads on IONQ or RGTI are attractive if either name reclaims prior highs without new contract or guidance catalysts; risk is a squeeze if federal equity headlines re-accelerate.
• Maintain a watchlist long GFS as an indirect policy beneficiary over 3-6 months: if U.S. industrial policy keeps broadening, domestic foundry assets can keep attracting incremental capital even when quantum stocks cool.
• Do not chase SKYT outright unless the IBM ecosystem evidence improves: acquisition optionality is real, but integration and timing risk are high; wait for confirmation that the IBM ecosystem is translating into revenue, not just narrative.